2021
A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome
Bloch MH, Landeros-Weisenberger A, Johnson JA, Leckman JF. A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome. Journal Of Neuropsychiatry 2021, 33: 328-336. PMID: 34340527, DOI: 10.1176/appi.neuropsych.19080178.Peer-Reviewed Original ResearchConceptsTourette syndromeTic symptomsUncontrolled trialsYale Global Tic Severity Scale-Total Tic ScoreDouble-blind placebo-controlled trialAvailable evidence-based treatmentsPhase 2 pilot studyExtension phasePlacebo-controlled trialRefractory Tourette syndromeTotal tic scoreEffective pharmacological treatmentCannabis-derived compoundsEvidence-based treatmentsTHC dosingSecondary outcomesPrimary outcomeComorbid conditionsPharmacological treatmentTic scoreYGTSS scoresTherapeutic combinationsSide effectsTrial designSyndrome
2020
Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders
Zhou MS, Nasir M, Farhat LC, Kook M, Artukoglu BB, Bloch MH. Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2020, 60: 35-45. PMID: 32387445, DOI: 10.1016/j.jaac.2020.03.007.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsPlacebo-controlled trialPharmacological treatmentPharmacological agentsAvailable pharmacological agentsAutism spectrum disorderSerotonin reuptake inhibitorsStandardized mean differenceStandardized study designsTreatment of ASDPharmacologic treatmentPrimary outcomeReuptake inhibitorsAntipsychotic medicationSpecific assessment toolsFolinic acidSpectrum disorderModest benefitRepetitive behaviorsMean differenceStudy designSmall effect sizesIndividual studiesTrialsPlacebo
2019
The Potential of Cannabinoid-Based Treatments in Tourette Syndrome
Artukoglu BB, Bloch MH. The Potential of Cannabinoid-Based Treatments in Tourette Syndrome. CNS Drugs 2019, 33: 417-430. PMID: 30977108, DOI: 10.1007/s40263-019-00627-1.Peer-Reviewed Original ResearchConceptsTourette syndromeCannabinoid systemAdult populationPositive urine drug screenBiological rationaleCannabinoid-based treatmentsPotential of cannabinoidsTourette syndrome populationsPlacebo-controlled trialTreatment of ticsUrine drug screensNovel pharmacological treatmentsCannabis-derived compoundsStrong biological rationaleCurrent evidence baseComprehensive literature searchDevelopmental adverse effectsRefractory patientsSafety profilePharmacological treatmentClinical trialsTic disordersUncertain efficacyFurther trialsSyndrome population
2018
A Systematic Review of Pharmacologic Treatments for School Refusal Behavior
Tobon A, Reed MO, Taylor JH, Bloch MH. A Systematic Review of Pharmacologic Treatments for School Refusal Behavior. Journal Of Child And Adolescent Psychopharmacology 2018, 28: 368-378. PMID: 29741917, PMCID: PMC6909768, DOI: 10.1089/cap.2017.0160.Peer-Reviewed Original ResearchConceptsSchool refusalSystematic reviewPharmacologic treatmentFuture pharmacologic studiesSpecific psychosocial treatmentsLong-term outcomesNew pharmacologic agentsImportant pediatric problemSchool refusal behaviorComprehensive literature searchSignificant methodological limitationsImportant functional outcomesSecondary outcomesFunctional outcomeNewer antidepressantsPharmacologic trialsPharmacological treatmentPharmacologic agentsPharmacological interventionsPsychological interventionsPharmacologic studiesPsychosocial treatmentsMost trialsPediatric problemAnxiety symptomsChapter 17 Managing a Child With OCD Who Is Treatment Refractory
Bloch M. Chapter 17 Managing a Child With OCD Who Is Treatment Refractory. 2018, 329-356. DOI: 10.1016/b978-0-12-811427-8.00017-4.Peer-Reviewed Original ResearchObsessive-compulsive disorderTreatment-refractory obsessive-compulsive disorderCognitive behavioral therapyFirst-line treatmentOCD symptomsPediatric obsessive-compulsive disorderSelective serotonin reuptake inhibitor (SSRI) pharmacotherapyEffective first-line treatmentSelective serotonin reuptake inhibitorsIntensive treatment programSerotonin reuptake inhibitorsGlutamate-modulating agentsMajority of childrenTreatment programAntipsychotic augmentationReuptake inhibitorsTreatment refractoryPharmacological treatmentAvailable treatmentsChildrenSubstantial proportionPharmacotherapyTreatmentTherapySymptoms
2016
N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Yaffa A, Alvarenga PG, Jakubovski E, Mulqueen JM, Landeros-Weisenberger A, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of Child And Adolescent Psychopharmacology 2016, 26: 327-334. PMID: 27027204, PMCID: PMC6445198, DOI: 10.1089/cap.2015.0109.Peer-Reviewed Original ResearchConceptsBenefit of NACEfficacy of NACYale Global Tic Severity ScaleAttention-deficit/hyperactivity disorderObsessive-compulsive disorderTourette syndromeN-acetylcysteineObsessive-compulsive spectrum disordersSide effectsRecent placebo-controlled trialPediatric Tourette syndromePlacebo-controlled trialCurrent pharmacological treatmentsTreatment of ticsTotal tic scoreSeverity of ticsSubstantial side effectsTic Severity ScaleYears of ageMinimal side effectsPediatric TSPrimary outcomeSecondary outcomesGlutamatergic systemPharmacological treatment
2015
Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder
Varigonda AL, Jakubovski E, Taylor MJ, Freemantle N, Coughlin C, Bloch MH. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 557-564. PMID: 26088660, DOI: 10.1016/j.jaac.2015.05.004.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsPediatric major depressive disorderMajor depressive disorderSerotonin reuptake inhibitorsSSRI agentsReuptake inhibitorsPediatric depressionDepressive disorderAdult major depressive disorderFirst-line pharmacological treatmentEarly treatment responseIndividual patient dataStandardized mean differenceMDD trialsSSRI doseSSRI pharmacotherapyPlacebo groupAdult patientsSSRI responsePharmacological treatmentPharmacological trialsTreatment responsePooled estimatesPharmacological responseHigh doses
2014
Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger C, Bloch MH. Pharmacological Treatment of Obsessive-Compulsive Disorder. Psychiatric Clinics Of North America 2014, 37: 375-391. PMID: 25150568, PMCID: PMC4143776, DOI: 10.1016/j.psc.2014.05.006.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPharmacological treatmentLow-dose neuroleptic medicationsSelective serotonin reuptake inhibitorsProfound clinical challengeSecond-line treatmentSerotonin reuptake inhibitorsSignificant symptomatic reliefTricyclic clomipramineAppropriate pharmacotherapyNeuroleptic medicationReuptake inhibitorsSubstantial morbiditySymptomatic reliefAvailable treatmentsClinical challengeHigh dosesOCD refractoryTreatmentDisordersMedicationsMorbidityPharmacotherapyPatientsClomipramineMeta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders
Ferracioli-Oda E, Qawasmi A, Bloch M. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. FOCUS The Journal Of Lifelong Learning In Psychiatry 2014, 12: 73-79. DOI: 10.1176/appi.focus.12.1.73.Peer-Reviewed Original ResearchPrimary sleep disordersTotal sleep timeOverall sleep qualityEffect of melatoninSleep disordersSleep qualitySleep latencySleep timeBenign side effect profilePlacebo-controlled trialSide effect profileEfficacy of melatoninTreatment of insomniaSleep onset latencyInfluence of doseDuration of melatoninMelatonin dosePrimary outcomeAbsolute benefitMelatonin usePharmacological treatmentSignificant efficacyNineteen studiesSleep parametersOnset latency
2013
Meta-analysis: pharmacological treatment of pathological gambling
Bartley CA, Bloch MH. Meta-analysis: pharmacological treatment of pathological gambling. Expert Review Of Neurotherapeutics 2013, 13: 887-894. PMID: 23952195, DOI: 10.1586/14737175.2013.814938.Peer-Reviewed Original ResearchConceptsStandardized mean differenceReported efficacyPharmacological treatmentOpiate antagonistPathological gamblingPlacebo-controlled trialBenefits of medicationsCurrent trial dataFixed-effects modelTreat principleNon-significant effect sizeITT principlePharmacological agentsMeta-AnalysisTrial dataPublication biasSecondary analysisPlaceboMean differenceAntagonistTrialsMedicationsEfficacyYear of publicationEffect sizeMeta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. PLOS ONE 2013, 8: e63773. PMID: 23691095, PMCID: PMC3656905, DOI: 10.1371/journal.pone.0063773.Peer-Reviewed Original ResearchConceptsPrimary sleep disordersTotal sleep timeOverall sleep qualityEffect of melatoninSleep disordersSleep qualitySleep latencySleep timeBenign side effect profilePlacebo-controlled trialSide effect profileEfficacy of melatoninTreatment of insomniaSleep onset latencyInfluence of doseDuration of melatoninMelatonin dosePrimary outcomeAbsolute benefitMelatonin usePharmacological treatmentSignificant efficacyNineteen studiesSleep parametersOnset latencySystematic Review and Meta-analysis of Pharmacological Treatment of the Symptoms of Attention-Deficit/Hyperactivity Disorder in Children with Pervasive Developmental Disorders
Reichow B, Volkmar FR, Bloch MH. Systematic Review and Meta-analysis of Pharmacological Treatment of the Symptoms of Attention-Deficit/Hyperactivity Disorder in Children with Pervasive Developmental Disorders. Journal Of Autism And Developmental Disorders 2013, 43: 2435-2441. PMID: 23468071, PMCID: PMC3787525, DOI: 10.1007/s10803-013-1793-z.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderADHD symptomsTrial of atomoxetineHyperactivity disorderPlacebo-controlled trialEfficacy of medicationsAdverse eventsPharmacological treatmentMethylphenidate trialMeta-AnalysisSystematic reviewSymptomsPervasive developmental disorderTrialsRelative efficacyIndividual trialsMedicationsDisordersChildrenDevelopmental disordersEfficacyPDDRandom effectsPlaceboClonidine
2011
The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis
Hannestad J, DellaGioia N, Bloch M. The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis. Neuropsychopharmacology 2011, 36: 2452-2459. PMID: 21796103, PMCID: PMC3194072, DOI: 10.1038/npp.2011.132.Peer-Reviewed Original ResearchConceptsMajor depressive disorderInflammatory cytokinesSerum levelsAntidepressant treatmentInterleukin-6Depressive symptomsIL-1βCytokine levelsDepressive episodeDiagnosis of MDDTumor necrosis factor alphaPharmacological antidepressant treatmentAntidepressant medication treatmentClasses of antidepressantsStratified subgroup analysisIL-1 betaNecrosis factor alphaNormalization of levelsReuptake inhibitorsMedication treatmentPharmacological treatmentSubgroup analysisBrain dysfunctionDepressive disorderFactor alphaPharmacological Treatment for Phobias and Anxiety Disorders
Bloch M, McGuire J. Pharmacological Treatment for Phobias and Anxiety Disorders. 2011, 339-354. DOI: 10.1007/978-1-4419-7784-7_23.Peer-Reviewed Original ResearchAnxiety disordersNew anxiety disordersPharmacological treatmentGeneral populationSuicide attemptsSubstance abuseDisorders